Doric Nimrod Air One Investors - DNA

Doric Nimrod Air One Investors - DNA

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Doric Nimrod Air One Limited DNA London Ordinary Share GG00B4MF3899 ORD PRF SHS NPV
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 33.00 08:00:15
Open Price Low Price High Price Close Price Previous Close
33.00 33.00 33.00 33.00 33.00
more quote information »
Industry Sector
EQUITY INVESTMENT INSTRUMENTS

Top Investor Posts

DateSubject
12/1/2017
10:01
danieldruff2: It may be that they never sell them, just keep leasing for the lifetime of the aircraft, by which point most of us will be old or gone, only pinch point is if major investors request a wind up of these vehicles and there is a forced sale.
15/12/2010
13:11
davydoo: A new thread to follow the performance of a new Special Purpose Vehicle that is planning to buy and lease one Airbus A380 to Emirates Airlines and provide an income and capital gain to investors. My personal interest is how this company performs in comparison to Avation (AVAP) and Capital Lease Aviation (CLA) which have portfolios of leased aircraft.
03/3/2009
15:05
grupo guitarlumber: Roche Gains as Genentech Talk Eases Price Concerns (Update1) Email | Print | A A A By Dermot Doherty March 3 (Bloomberg) -- Roche Holding AG rose the most in almost three months in Zurich trading after analysts said a presentation by Genentech Inc. didn't turn up new evidence that could push the Swiss drugmaker to overpay for its partner. Roche climbed as much as 7.2 Swiss francs, or 5.8 percent, to 131.3 francs, the biggest gain since Dec. 8. Genentech shares fell 4.6 percent yesterday. Genentech executives, trying to show Roche should raise its $42.1 billion bid, said yesterday the biotechnology company may begin selling 15 new drugs by 2015 and introduce 24 new uses for existing medicines, including the cancer drug Avastin. "There were no surprises in Genentech's presentation," said Carri Duncan, an analyst at Sal. Oppenheim in Zurich. "They had the platform and I don't think they impressed." Roche shares dropped 6.7 percent yesterday on concern about Genentech's presentation. Duncan and investors say the Swiss drugmaker will need to raise its bid. A shareholder survey by Citigroup Inc. last month found that 92 percent of Genentech holders won't tender their shares at the current price of $86.50. The concern centers around how high Roche may need to go. "What Roche investors are worried about is if they overpay," said Duncan, who expects a deal at $90 a share or above. Genentech estimates the company is worth at least $112. Roche last year extended a tender for a fifth time and increased its offer by 19 percent to buy U.S. diagnostics company Ventana Medical Systems Inc. for $3.4 billion. To contact the reporter on this story: Dermot Doherty in Geneva at Ddoherty9@bloomberg.net Last Updated: March 3, 2009 07:26 EST
01/2/2009
20:47
waldron: Why the Drop in Roche's Genentech Bid? by: Mike Huckman February 01, 2009 | about stocks: DNA / RHHBY.PK Mike Huckman Add to Your WatchlistAbout this author: Profile & More Articles Visit 'Pharma's Market' Visit CNBC.com Become a Contributor Submit an Article Font Size: PrintEmail TweetThis Genentech (DNA) shares dropped three percent Friday or $2.85 to $81.24 after Roche showed some chutzpah and lowered its bid for DNA. Recently, there'd been reports that the Swiss drugmaker, which already has a majority stake in the California biotech, was going to raise the offer to around $94. So, it was surprising and, some might say, shocking when Roche (RHHBY.PK) announced Friday morning that it was willing to pay $86.50 a share instead of the original $89. Late Friday, Genentech put out a press release urging shareholders to tell Roche to take a hike. Dr. Charles Sanders, the chairman of the special committee of the DNA Board of Directors that's been set up to deal with Roche, called Roche's move "unilateral and opportunistic...in an attempt to take advantage of current market conditions." But in a research note to clients, Bill Tanner at Leerink Swann said investors should take the money. "We believe the shares are fundamentally overvalued." Leerink Swann may trade in DNA. Other analysts and investors believe Genentech's stock could rally this spring when test results are expected on the cancer drug Avastin as an add-on treatment for colon cancer. If the data are good and the drug gets approved for that use, it could substantially increase Avastin sales. Genentech recently announced that the numbers could be available in April. I'm guessing it'll unveil the so-called topline data at that time and save the details to make a huge splash at this year's American Society of Clinical Oncology meeting. Geoffrey Meacham at JPMorgan says if that Avastin study goes well that Genentech shares could be worth more than a hundred bucks. "We do not expect the majority of shareholders to participate in this tender offer, where most of the core holders have held the stock for several years and are believers in the adjuvant (add-on Avastin colon cancer treatment) opportunity and the long-term value of the company." JPM has done and wants to do more investment banking for DNA and it makes a market in DNA options, which were apparently active Friday. And another Geoffrey...Geoffrey Porges at Sanford C. Bernstein writes, "This is clearly another high risk hardball negotiating strategy by Roche. We believe it has a significant risk of failing to impress sufficient Genentech independent shareholders to close the deal." A part of Bernstein owns at least one percent of DNA.
23/1/2009
17:22
waldron: Roche Faces Big Decision On Genentech Bid As Key Data Loom By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Roche Holding AG (RHHBY) has consistently reiterated its devotion to buying the 44% of Genentech Inc. (DNA) that it doesn't already own, but the potential early arrival of a key study means the company may have to decide its next step soon. If the Swiss drugmaker waits for the data regarding Genentech's flagship cancer drug Avastin, possibly coming in mid-April, and the results are considered a success, Roche risks paying significantly more than the already rejected offer of $89 a share. If the study fails, it could pay less. Roche can also decide not to take the gamble, but it needs to move soon to cut a deal with Genentech and get financing amid tight credit markets. "I honestly think it could be any day now," Robert Baird & Co. analyst Chris Raymond said, referring to his expectations for a higher bid. If a deal is reached soon, Wall Street generally expects it to be higher than $95 a share. A successful study could drive Genentech's value above $100, excluding any premium from a Roche offer, while its failure may actually bring Roche to lower its rejected offer from July. Shares of Genentech, recently at $83.94, have traded below the offer price since late September, after hitting a high of $99.14. The drop reflects doubts about Roche's ability to close the deal amid tight credit markets, rather than concerns related to the forthcoming study. Roche shares recently fell 1.22% to $36.30. Neither Roche nor Genentech would comment on the acquisition offer. Genentech's next few years will likely be driven by Avastin, which is approved to treat advanced breast, lung and colorectal cancer and had 2008 sales of $2.69 billion. The drug's future trajectory will be determined by its potential use in the adjuvant setting - when it is administered after cancer is surgically removed.Currently, Avastin is only used on cancer that has spread beyond its original site. Its use as an earlier treatment could add billions of dollars in sales, and the so-called C-08 study will be the first view of the drug's adjuvant use in colorectal cancer. The trial is being run by a third-party cooperative group and Genentech had expected the data to come in the middle of the year, but earlier this week disclosed it could be as early as mid-April. Most Wall Street analysts see colorectal adjuvant usage adding at least $1 billion in annual sales. Lazard Capital Markets recently estimated that adjuvant usage in breast, lung and colorectal cancer could ultimately bring more than $9 billion in additional annual sales. Genentech has acknowledged the importance of Avastin's adjuvant use to the drug's growth over the next three to five years, but also asserts that approval isn't essential. "I think people get understandably focused or even obsessed by the adjuvant result," said Ian Clark, executive vice president of commercial operations, in an interview last week. "I'm confident that we can continue to grow the business even without a positive adjuvant study." Back To The Wall The shorter timeline for the data's release puts Roche in the position of either raising its bid before such monumental data, or waiting to see the results and riding the inevitable shift in the value of the Genentech. "It's my view that both parties are incentivized to get this thing done before the data comes out," Raymond said. Roche recently said that the deal is on track, despite the ongoing financial crisis, and that it always expected the process to take a year from the original bid, according to The Wall Street Journal. But some believe that Roche always intended to close the deal before the announcement of the C-08 results, and now the timing shift has backed it into a corner. Some speculate that Roche will make a bid before releasing 2008 financial results on Feb. 4. Besides getting the approval of Genentech's independent board and from shareholders, Roche will have to line up financing amid the financial crisis. The deal would be huge: The original $44 billion offer goes up $500 million for every dollar added to the original $89-per-share bid. Analysts expect a deal somewhere above $95 per share, and many are aiming closer to $105 a share. The price to Roche is also higher as the U.S. dollar has strengthened against the Swiss Franc, adding 14% to the original bid in July, when Roche cited the weak dollar as a motivating factor for the deal. Rolling The Dice If Roche either can't get the deal done prior to the data, or it decides to take its chances, it is sure to provide a wild ride for Genentech shareholders. "If data are positive and Roche has not closed the deal, we suspect the price of Genentech will become too expensive for Roche to finance," said Morgan Stanley analyst Steven Harr. But success is not guaranteed, and negative data will likely have the opposite effect, possibly making Roche's previous $89-a-share offer look too expensive. "I don't know where Roche would come out in valuing Genentech at that point, but definitely it would be below $89," said RBC Capital Markets analyst Jason Kantor, noting that the original offer won't necessarily be on the negotiating table after the C-08 data because the independent board already rejected it. Any deal before the data release will likely include a large breakup fee or some other mechanism to avoid a renegotiation after the news comes out. In the meantime, until the data, most on Wall Street don't expect major changes to Genentech's share price as most investors are well aware of the risks regarding the deal and the study. "You are kind of crazy to own the stock if you don't think that the data is going to be positive," Kantor said. -By Thomas Gryta, Dow Jones Newswires; 201-938-2053; thomas.gryta@dowjones.com
17/1/2009
11:47
ariane: J.P.Morgan: Analyse de Roche 16/01/2009 - 11:48 - (Bolsamania) - Roche Genentech cautious 2009 Guidance should strengthen Roche's negotiation position – ALERT Yesterday, Genentech provided 2009E earnings guidance significantly below consensus. This should reduce the scope for Genentech's board of Directors to push for a significantly higher bid from Roche than the $89 they have already rejected. Importantly, the gap from guidance to consensus estimates can be attributed largely to well known headwinds that are already reflected in our current published Roche and Genentech estimates. In our view the shortfall of the guidance compared to consensus does not point to an unexpected deterioration of the Genentech operating performance, but rather to expectations by biotech investors that may have run ahead of themselves (to justify a request for a higher bid from Roche?). Reiterate Overweight rating for Roche. Genentech reported 4Q'08 results broadly in line with consensus (if retention payment are stripped out) but provided a relatively cautious outlook for 2009, guiding towards a 2009 non-GAAP EPS range of $3.55-3.90, implying y-o-y EPS growth ranging from +4 to +14%. 2009 guidance is in line with our Genentech projections in our published Roche model (2009E: $3.58), but significantly below consensus of $3.92. It appears that Genentech bulls may not have taken into account several known headwinds affecting Genentech's 2009E bottom line: (1) lower Rituxan royalties from Roche, (2) lower Herceptin collaborator sales to Roche, (3) FX headwinds on the royalty line (rather than the tailwind seen in recent years), (4) retention payments of $0.11 per share. Importantly, those headwinds have no effect on our Roche estimates: Rituxan royalty and Herceptin payments don't affect the Roche consolidated group figures whereas FX effects and retention payment are already reflected in our Roche estimates. (Note, Roche IFRS numbers do not add back either stock option expense or retention payments to earnings, in contrast, Genentech adds back stock options expenses to non-GAAP earnings, but deducts retention payments from non-GAAP estimates, due to their cash nature.) Potential Raptiva withdrawal is the only new element that may negatively affect Genentech as well as Roche 2009E bottom line, with a potential negative EPS impact of $0.05 for Genentech or 0.3% on Roche EPS. We expect to learn in coming weeks to what extend this risk will materialise, as discussions with regulators about two cases of PML progress.
03/12/2008
17:01
ariane: HEALTH BLOG WSJ's blog on health and the business of health. Blog Search: < Problems in Primary Care Drive ER Crowdi[...] -- Previous | SEE ALL POSTS FROM THIS BLOG | December 3, 2008, 10:54 am Genentech Carries On, as Roche Deal Simmers on Back Burner Posted by Ron Winslow Roche's blockbuster bid for the portion of Genentech it doesn't own has stalled amid the credit crisis and stock market plunge, and concern persists over the impact of the proposed transaction on the biotech pioneer's culture and productivity. Not to worry - at least for now, said Stephen Kelsey, the company's VP for clinical hemotology/oncology. The Health Blog dropped in on the Genentech presentation this morning at Piper Jaffray's annual health care conference in Manhattan where Kelsey said Roche's $44 billion offer hasn't had any discernible effect on employee retention or morale. People come to Genentech because it's a good place to work and because they believe the work is important, he said. "Until that changes, they'll continue to work there." A big employee retention program the company announced shortly after the bid may have helped. Kathee Littrell, VP for investor relations, added that business development deals haven't been affected either. A special committee of Genentech's board rejected Roche's $89-a-share bid in August as substantially under-valuing the company, but opened the door to a higher bid. With the company's shares currently trading at around $73, the market seems to be saying there won't be a deal anytime soon. Neither Kelsey nor Littrell had any comment on the status of the proposed transaction itself. Perhaps more pressing is how biotech-friendly, or not, the incoming Obama adminstration and a heavily Democratic Congress will prove to be. One worry, Kelsey said, is the details of expected legislation to pave the way for approval of generic biotech drugs - the industry likes to call them follow-on biologics. (We still call them generics.) Genentech, like its biotech brethren believes companies companies wanting to bring, say, a Herceptin knockoff to market should be required to prove its similarity to the real McCoy with data from a substantial clinical trial-not just a relatively simple lab analysis that is required to get conventional generics to the market. High on the list of other concerns, Kelsey said, are the potential that medicare would be allowed to negotiate prices with drugmakers and whether NICE in the U.K. becomes a model for assessing value of drugs in the U.S. Photo: Associated Press
15/5/2008
07:31
grupo guitarlumber: Global market expected to drive cancer drug growth WASHINGTON (AP) - The global market for cancer drugs will grow twice as fast as that for all other pharmaceuticals as the developing world spends more on health care, a new report says. China, Brazil, Russia and other emerging countries are becoming bigger customers for pharmaceuticals as they invest more in treating and diagnosing cancer, according to a report issued Thursday by IMS Health. The health care research firm expects pharmaceutical spending in countries such as India, Mexico and Turkey to grow by 12 to 13 percent over the next 15 years, compared with single-digit growth for more developed nations. Cancer drug spending is expected to grow between 12 and 15 percent annually through 2012 to $75 to 80 billion, according the report. The overall drug market is expected to grow at 6.4 percent. Feeding that demand are the multibillion-dollar research and development budgets of firms like Genentech Inc., Amgen Inc. and Novartis AG. "Oncology is the top of the bill when it comes to new products in development," said Titus Pattel, a vice president with IMS. "Oncology R&D dwarfs all other research efforts within these organizations." Cancer drug sales are expected to reach $48 billion this year, led by Genentech's breast cancer drug Herceptin, Novartis' leukemia drug Gleevec and other blockbusters. But the market is not immune to a slowdown. Expiring patents on older cancer drugs and efforts to tighten health care spending could limit future growth, according to IMS. Some European countries have begun paying drug companies based on how successfully their drugs treat patients. The Italian government, for example, only began reimbursing Johnson & Johnson for the cancer treatment Velcade after the drug demonstrated positive results in patients. IMS said that the adoption of similar policies in the U.S. it could slow spending on cancer medications. Pharmaceutical firms also face a tougher regulatory environment in the U.S., where the Food and Drug Administration has delayed several highly anticipated cancer therapies. Last year, the agency denied approval of Dendreon's prostate cancer vaccine Provenge, despite an overwhelmingly positive review by the agency's outside advisers. "There's a tendency from the FDA to be more conservative than they have over the last 10 years," Pattel said. An aggressive review environment could dampen the market for between 25 and 30 new anticancer drugs currently in development, the IMS report says. At the same time, some of the biggest blockbuster cancer drugs of the last decade will lose their patent protection, including Sanofi-Aventis' Taxotere and AstraZeneca PLC's Arimidex. Expiring drug patents and an increasingly crowded market for cancer therapies will lower spending in the U.S. and Europe. These markets are expected to account for 65 percent of the global cancer drugs market by 2012, down from 71 percent last year, according to IMS. The company's forecast comes ahead of the American Society of Clinical Oncology's annual meeting, which begins May 30. Abstracts for company studies will be released online Thursday night, giving researchers and investors a preview of clinical results for experimental drugs.
03/2/2008
15:26
waldron: http://www.telegraph.co.uk/money/main.jhtml?view=DETAILS&grid=&xml=/money/2008/01/25/bcn23andme.xml Google wife targets world DNA domination By Felix Lowe Last Updated: 11:54pm GMT 30/01/2008 Her husband is one of the world's richest men who has built up an internet empire that delivers and classifies digital information at the click of a mouse. The latest news and views from Davos Now Anne Wojcicki is planning to tap into the rise of online global networking to help people make sense of their own genetic information. Anne Wojcicki And if her business expectations are anything to go by, she shares much of the ambition and drive of her husband, the billionaire co-founder of Google, Sergey Brin. Co-founder of biotech company 23andme, Wojcicki has been at the World Economic Forum in Davos this week to drum up interest in the European launch of the web-based DNA service. "We'd like to reach 98pc of the world, that is our goal," says Wojcicki from beside her fledgling company's booth on the first floor of the Belvedere Hotel. "You have to have high standards to get anywhere in life, and if genealogy continues at its current rate, what we're offering will soon become a standard part of people's lives." Named after the number of chromosomes that make up each person's genome, 23andme operates by analysing saliva samples to build up a picture of its clients' inherited traits, ancestry and, in time, personal disease risks. Customers send in their saliva - along with a hefty cheque for $999 - and four to six weeks later receive their results online. They have a personal profile set up outlining anything from their athletic ability to their food preferences and sleep habits. If they chose to do so, customers can then exchange their information with family and friends to build up a better understanding of both themselves and their ancestry. It may seem far-fetched, but Wojcicki, 33, and her 47-year-old business partner Linda Avey reckon their service represents the future of social networking. In the same way that the likes of MySpace, Facebook, You Tube and Flickr allow users to share information - in the shape of videos, photos or instant messaging - Wojcicki and Avey can see a time where people worldwide will share and compare their genetic details. The pair decline to say how many customers they've had since their launch in the US in November. "Amazing things are going to happen in the next five years or so," assures Wojcicki. "There will be an extraordinary evolution in our product and in genetics on the whole. After the success we've had in the US, Europe and Canada is the obvious next stage. "But genealogy is a global phenomenon and ultimately we're looking at the worldwide stage." But surely targeting 98pc of the world's 6.7bn population is pushing it a little, especially given lavish cost of the service? Linda Avey "It is an expensive product," concedes Avey, "but this is definitely the way of the future. The world is heading in the direction where everyone will soon have access to their genetic information. The interest shown in our service is already staggering, and technology costs will drop. They have already dropped 5,000 times in the last couple of years." The pair use the example of plasma TVs ("a novelty in the 90s") and mobile phones - both of which are now readily available across the globe at relatively little cost. 23andme has benefited itself from a $3.9m investment from Google and other investors include biotechnology corporation Genentech and New Enterprise Associates, a information technology and healthcare investments specialist. "Our investors have made things move much faster," says Wojcicki. "It's very empowering to have innovative companies that believe in you and understand the concept." Wojcicki says that while her husband has been extremely supportive of the business, he has abstained from any involvement so as not to create a conflict of interest. "23andme is very independent and committed to focusing on transparency," stresses Wojcicki. "The Google investment was so attractive because they are a huge company which is very good at organising the world's information. To them, genetics is just another form of information. "This whole project is about releasing information into the world, a way of putting valuable information in a more accessible format. "But privacy and the security of data is a primary concern to us, it's an on-going mission. Our service is as secure as it can be and we would never share data with Google or with anyone without the wishes of our customers." Wojcicki, who has a strong history of working in the healthcare sector, expects the social side of their product to drive demand, at least initially. "It's not that we're against the medical research side of things," she says. "On the contrary, that is where our long term interests lie. But the genetic profiles are in their preliminary stage and it's too early to be making predispositions and alarming people with the findings. It's the social networking side of things that will help the product take off." The 'I spat!' 23andme Davos beanie hats 23andme is using the opportunity of Davos - the annual jamboree of business leaders, politicians and assorted celebrities - to roadtest the product in Europe. A stand opposite the lift on the first floor of the Belvedere Hotel is an ideal platform from which to promote the service. "We're stopping everyone that comes past," says Wojcicki, armed with 1,000 free spit kits and some fetching grey beanie hats, emblazoned with the words 'I spat!'. "Early spitters" include the digital entrepreneur Esther Dyson - a board member of 23andme - and the supermodel Naomi Campbell. Thanks to the investment from the likes Google, 23andme is expanding rapidly and is constantly on the lookout for young, talented engineers, health experts and IT specialists. So doesn't Brin fit the bill? "Having someone like Sergey - with all his engineering skills and experience - working for me would add a lot of value," says Wojcicki, without a hint of irony. "We're doing our best to poach him. We've even offered to double his salary to two dollars, but so far we have not been successful in luring him away from Google."
16/10/2007
06:51
waldron: Genentech 3Q profit increases 21 percent SAN FRANCISCO (AP) - Genentech Inc. barely beat Wall Street estimates for the third quarter, and many analysts are skeptical that world's second-largest biotech company can maintain its scorching momentum amid new competition and a saturated market. Genentech reported Monday that net profit in the three months ended Sept. 30 was $685 million, or 64 cents per share, up 21 percent from $568 million, or 53 cents per share, in the same period a year ago. Revenue was $2.91 billion, up 22 percent from $2.38 billion in the third quarter last year. Not counting expenses, including those related to the $919 million buyout of biotechnology company Tanox Inc. last quarter, the company earned $778 million, or 73 cents per share, up 22 percent from a year ago. On that basis, which does not comply with generally accepted accounting principles, analysts expected Genentech to earn 72 cents per share on revenue of $2.93 billion. Executives at the South San Francisco-based company said in a conference call Monday they were particularly happy about their $597 million in third-quarter sales of Avastin, which treats lung, breast and colon cancer. That's 37 percent more than in the year-ago quarter and several million dollars more than analysts had expected. Genentech's partner on Avastin, Swiss health care giant Roche, received European approval for the drug as a treatment for certain forms of lung cancer. Genentech is seeking approval from the Food and Drug Administration to use Avastin as a treatment for metastatic breast cancer, or breast cancer that has spread to other parts of the body. Genentech is also running tests to determine whether Avastin, also known as bevacizumab, is effective in "adjuvant therapy," the attempt to prevent the recurrence of a cancer after a tumor is surgically removed. But biotechnology analysts say such new uses are incremental and Avastin may have already saturated its primary market. "The double-edge sword of oncology is you get rapid adoption, but you tend to reach full saturation quickly," said Lehman Brothers equity analyst Jim Birchenough. He is forecasting net income growth of around 10 percent per year for several years -- far lower than the 20 percent or more that many investors are hoping for, based on the company's relatively lofty stock price-to-earnings ratio. Avastin -- which the FDA approved in February 2004 as the first drug to thwart new blood vessels from developing and carrying nutrients to a tumor -- is facing more competition. Britain's GlaxoSmithKline PLC announced in March that its Tykerb was approved for treatment of patients with advanced or metastatic breast cancer who have received prior therapy. New York-based ImClone Systems Inc.'s Erbitux was also approved in 2004 to treat advanced colorectal cancer that has spread to other parts of the body. Analyst Eric Schmidt said Genentech is relying too heavily on Avastin, the company's only drug with a year-over-year growth rate of at least 30 percent. Total U.S. product sales were $2.16 billion, up 18 percent from the third quarter last year. "Avastin had good growth, but the others have hit a wall," said Schmidt, who works for equity research firm Cowen & Co. "The hope is that Avastin can lead the charge, but that's dependent on whether Avastin works in adjuvant therapy." Genentech's second biggest source of revenue, Rituxan, approved to treat rheumatoid arthritis and non-Hodgkin's lymphoma, brought in $572 million last quarter. That's up 12 percent from than a year ago. Sales of its breast cancer drug Herceptin rose 6 percent to $320 million. Genentech's macular degeneration drug Lucentis, approved in June 2006, had sales of $198 million, a 29 percent jump. Lucentis is designed to inhibit the formation and leakage of new blood vessels in the back of the eye, the primary cause of central vision loss. Sales of asthma drug Xolair increased 13 percent to $121 million. Xolair is designed to control asthma triggered by year-round allergens, and executives are bullish that the drug will soon be used to treat the growing incidence of pediatric asthma. Genentech spent $578 million on research and development, up 38 percent from the third quarter of last year. The company reaffirmed its outlook for full-year profit between $2.85 and $2.95 per share, excluding charges. Wall Street analysts were predicting earnings of $2.95 per share. Shares of Genentech gained 25 cents to $77.50 before the results were released at the end of regular trading. Genentech shares lost 70 cents after-hours. Sales leader Amgen Inc.'s shares fell 50 cents to $57.67 for a market capitalization of $62.7 billion. In after-hours trading, Thousand Oaks-based Amgen regained 50 cents. Genentech is the biggest biotechnology company based on market capitalization, valued at $81.6 billion. It has a price-to-earnings ratio -- a common measure of Wall Street's bullishness for a stock -- of 31.8. By contrast, Amgen's ratio is 16.6.
ADVFN Advertorial
Your Recent History
LSE
DNA
Doric Nimr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 05:19:26